MYL9 (Ab-19) Antibody

What is MYL9 and what cellular processes does it regulate?

MYL9 (Myosin Regulatory Light Polypeptide 9) is a 19.8 kDa protein comprising 172 amino acid residues that primarily localizes to the cytoplasm . It functions as a myosin regulatory subunit that plays an essential role in regulating contractile activity in both smooth muscle and non-muscle cells through its phosphorylation state . MYL9 is implicated in critical cellular processes including:

• Cytoskeletal organization and contractility

• Cell migration and locomotion

• Cytokinesis during cell division

• Receptor capping mechanisms

• PIEZO1-dependent cortical actomyosin assembly (particularly relevant in myotube formation)

The protein exists in multiple isoforms due to alternative splicing, with at least two confirmed variants . Understanding these fundamental properties is crucial for designing appropriate experimental protocols when using MYL9 antibodies.

What detection methods work best with MYL9 antibodies?

According to comprehensive analyses of research applications, the following methods demonstrate optimal efficacy for MYL9 detection:

For western blotting, researchers should note that MYL9 antibodies have been validated in human, mouse and rat samples . When selecting antibodies, consider whether total or phospho-specific detection is required for your experimental design .

How should researchers validate MYL9 antibody specificity?

Robust validation requires multiple approaches:

• Knockout/knockdown validation: Use MYL9 knockout cell lines (e.g., HeLa MYL9 knockout) to confirm antibody specificity. Loss of signal in knockout samples confirms specificity .

• Phosphorylation-state specificity: For phospho-specific antibodies, validate with phosphatase treatment of lysates to ensure the antibody genuinely detects the phosphorylated form only .

• Cross-reactivity assessment: Test for cross-reactivity with related myosin light chain proteins, particularly MYL12A and MYL12B, which share structural similarities with MYL9 .

• Peptide competition: Pre-incubation with immunizing peptide should abolish specific signals in applications like immunohistochemistry or western blotting .

• Multiple antibody concordance: Compare results using antibodies raised against different epitopes of MYL9 to ensure consistent findings.

How can MYL9 antibodies be utilized to study epithelial-mesenchymal transition in cancer research?

Recent studies reveal MYL9's critical role in epithelial-mesenchymal transition (EMT), particularly in non-small-cell lung cancer (NSCLC), where it functions as a tumor suppressor . For researchers investigating this phenomenon:

• Protein expression analysis: Use validated MYL9 antibodies in western blotting to compare MYL9 expression levels between normal and cancer tissues/cell lines. Bioinformatics analysis has revealed significant downregulation of MYL9 in NSCLC compared to normal tissues .

• EMT marker correlation: Combine MYL9 antibody detection with EMT marker analysis (E-cadherin, vimentin, N-cadherin). Research has shown that MYL9 knockdown reduces E-cadherin expression while increasing vimentin and N-cadherin levels, indicating EMT acceleration .

• Protein interaction studies: Employ co-immunoprecipitation with MYL9 antibodies to identify binding partners. The MYL9-MYO19 interaction has been demonstrated using this approach, revealing a mechanism through which MYL9 suppresses EMT .

• Migration assays with antibody validation: When conducting scratch wound healing assays to assess migration capacity, use MYL9 antibodies to confirm knockdown or overexpression efficiency .

• Flow cytometry applications: MYL9 expression alterations affect cell surface markers like EpCAM. Flow cytometric analysis with MYL9 antibodies can help elucidate these relationships .

What methodological considerations are important when using phospho-specific MYL9 antibodies?

Phosphorylation state-specific antibodies present unique challenges and opportunities:

• Epitope selection: Phospho-specific antibodies targeting Ser18 (human), Ser20 (mouse), or Ser19 (rat) enable species-specific detection of activated MYL9 . The selection of appropriate phospho-epitopes is crucial for experimental design.

• Sample preparation: Rapid fixation/lysis is essential to preserve phosphorylation status. Flash-freezing tissues and adding phosphatase inhibitors to lysis buffers are critical steps .

• Specificity verification: Phospho-specific MYL9 antibodies should detect the protein only when phosphorylated at the specified residue (e.g., Ser18). This can be verified through phosphatase treatment of samples .

• Purification considerations: The highest quality phospho-specific antibodies undergo dual purification, first with the phosphopeptide for positive selection, followed by non-phosphopeptide chromatography to remove antibodies recognizing the non-phosphorylated form .

• Experimental controls: Include both phosphorylation-inducing and phosphorylation-inhibiting conditions to validate antibody specificity and sensitivity.

How can researchers effectively use MYL9 antibodies to study cancer progression mechanisms?

Recent research demonstrates divergent roles of MYL9 in different cancer types, highlighting the need for careful experimental design:

• Tumor-specific expression profiling: In NSCLC, MYL9 functions as a tumor suppressor and is downregulated , while in colorectal cancer, it promotes proliferation, invasion, and migration . Researchers should use antibodies to establish baseline expression in their specific cancer model.

• Functional studies with validated knockdown/overexpression: When investigating MYL9's functional role, combine siRNA knockdown or overexpression with antibody detection to confirm manipulation efficiency .

• Interaction screening approaches: For identifying novel binding partners, use MYL9 antibodies in pull-down assays followed by mass spectrometry. The BioGRID database analysis approach that identified MYO19 as an MYL9 binding partner demonstrates this method's value .

• Integrating signaling pathway analysis: In colorectal cancer, MYL9 activates Hippo signaling through YAP1 binding , while in NSCLC, it regulates EMT through MYO19 . Using antibodies against pathway components alongside MYL9 detection provides mechanistic insights.

• In vivo validation: Immunohistochemistry with MYL9 antibodies on patient tissues correlates expression patterns with clinical outcomes, as demonstrated in Kaplan-Meier analyses for MYO19 in NSCLC .

How can MYL9 antibodies be used to investigate inflammatory and vascular pathologies?

Recent studies highlight MYL9's role beyond cancer, particularly in inflammatory conditions:

• Plasma level measurements: ELISA using MYL9 antibodies can quantify circulating MYL9 levels, which are significantly elevated in inflammatory conditions like Kawasaki disease .

• Platelet activation studies: MYL9 can be released by platelets during inflammatory responses. Flow cytometry with MYL9 antibodies helps detect this release mechanism, especially relevant in vascular inflammation research .

• Tissue localization in vasculitis: Immunohistochemistry reveals MYL9 expression patterns in different vascular compartments (intima, adventitia) during acute and chronic phases of vascular inflammation .

• Prognostic biomarker validation: MYL9 antibody-based assays can potentially serve as biomarkers for treatment response, as demonstrated in IVIG therapy studies where MYL9 levels declined in responders but not in non-responders .

• Animal model correlation: Combining antibody detection in both human samples and animal models (like LCWE-injected mice) strengthens translational relevance of findings .

What are the technical considerations for using MYL9 antibodies in multiplex immunofluorescence studies?

Researchers employing multiplex approaches should consider:

• Antibody compatibility: When combining MYL9 antibodies with other markers, verify spectral separation of secondary antibodies and test for cross-reactivity.

• Epitope retrieval optimization: Different epitopes may require specific retrieval methods; optimize conditions to maintain detectability of all target proteins without compromising MYL9 signal integrity.

• Signal amplification strategies: For low-abundance targets, consider tyramide signal amplification methods compatible with MYL9 antibody detection.

• Sequential staining protocols: To avoid cross-reactivity between antibodies from the same species, consider sequential staining with complete stripping between rounds or use directly conjugated primary antibodies.

• Quantification standards: Include calibration controls for accurately quantifying relative expression levels when comparing MYL9 with other proteins of interest.

How can researchers troubleshoot inconsistent results when using MYL9 antibodies?

Common technical issues and their solutions include:

• Variable phosphorylation states: MYL9 functionality depends on its phosphorylation state, which can change rapidly during sample processing. Standardize tissue collection and fixation times, and consistently use phosphatase inhibitors .

• Antibody cross-reactivity: Due to homology with other myosin light chain proteins (particularly MYL12A/B), some antibodies detect multiple targets. Use knockout validation or highly specific antibodies that differentiate between family members .

• Expression level differences: MYL9 expression varies significantly across tissue types and disease states. Adjust protein loading amounts and exposure times accordingly.

• Non-specific signals: Optimize blocking conditions and antibody concentrations. For phospho-specific antibodies, confirm specificity using phosphatase treatment of control samples .

• Inconsistent immunoprecipitation results: For binding partner studies, try multiple lysis conditions as interaction stability may depend on buffer composition.

What emerging roles of MYL9 should researchers consider exploring with antibody-based approaches?

Based on recent findings, several promising research directions emerge:

• Dual roles in different cancer types: Investigate the mechanisms behind MYL9's apparently contradictory functions as a tumor suppressor in NSCLC versus an oncogenic promoter in colorectal cancer .

• Novel protein interactions: Beyond MYO19 and YAP1, use immunoprecipitation with MYL9 antibodies to identify additional binding partners that may explain tissue-specific functions.

• Extracellular MYL9 functions: Recent evidence showing MYL9 release from platelets suggests potential extracellular roles beyond its canonical intracellular functions .

• Therapeutic targeting potential: Explore whether modulating MYL9 activity or its interactions could have therapeutic value in cancer or inflammatory conditions.

• Biomarker development: Further validate MYL9 as a biomarker for disease progression or treatment response in conditions like Kawasaki disease or various cancers using antibody-based assays .

How can researchers best integrate MYL9 antibody data with other molecular profiling approaches?

Comprehensive research requires integrating multiple methodologies:

• Correlation with transcriptomic data: Compare protein-level findings using MYL9 antibodies with RNA-seq data to identify post-transcriptional regulation mechanisms.

• Phosphoproteomic integration: Combine phospho-specific MYL9 antibody data with global phosphoproteomic profiling to position MYL9 within signaling networks.

• Single-cell analysis: Apply MYL9 antibodies in single-cell western blotting or mass cytometry to capture cellular heterogeneity not visible in bulk analyses.

• Spatial transcriptomics correlation: Compare MYL9 protein localization using immunohistochemistry with spatial transcriptomics data to identify microenvironmental influences on expression.

• Systems biology approaches: Incorporate MYL9 antibody data into pathway analyses and protein interaction networks to generate testable hypotheses about its functional role in complex biological systems.